Nucleo
Nucleo is an AI-powered medical imaging platform that automates CT scan analysis for oncology care, delivering body composition assessment, tumor lesion sizing, and RECIST-compliant lesion classification to hospitals in the US and internationally.
- Company typePrivate
- Founded2025
- HeadquartersSan Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Nucleo does
Nucleo Research ("Nucleo") is an early-stage healthcare AI company that automates CT scan analysis for oncology care. The platform delivers three integrated capabilities: automatic body composition and sarcopenia assessment (quantifying fat and muscle mass), precise tumor lesion sizing, and automated target vs. non-target lesion classification per RECIST criteria. Its stated value proposition is faster-than-manual segmentation with high agreement (reported as 95%) between Nucleo's outputs and expert radiologist analysis, addressing the time and consistency bottlenecks in oncology imaging workflows.
The underlying technology is computer vision applied to CT/DICOM medical images, built on NVIDIA-powered infrastructure. The product is delivered as a software platform targeted at hospitals and oncology departments, with no disclosed API or SDK and no disclosed regulatory clearance (e.g., FDA pathway). Distribution is direct enterprise sales via a consultative demo motion (Cal.com booking), and the company is backed by Y Combinator and works with hospitals in the US and internationally. All public-facing technical claims (accuracy, speed) are vendor-reported; no independent validation, peer-reviewed studies, or patents are disclosed in the source material.
Nucleo is privately held, headquartered in San Francisco, founded in 2025, and operates with 1–10 employees. Its only disclosed funding event is a $500,000 Y Combinator-led round dated December 3, 2025. The revenue model is best characterized as quote-based enterprise SaaS for healthcare institutions, though pricing is not publicly disclosed and the company is most likely at a pre-revenue or early-pilot commercial stage given its recency, headcount, and capital base.
Nucleo firmographics
Firmographics- Name
- Nucleo
- Legal name
- Nucleo Research
- Website
- https://nucleoresearch.com
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Nucleo is an AI-powered medical imaging platform that automates CT scan analysis for oncology care, delivering body composition assessment, tumor lesion sizing, and RECIST-compliant lesion classification to hospitals in the US and internationally.
- Ownership category
- akta.pro rank
Nucleo industry classification
Industry- Product category
- AI Oncology Imaging Software
- NAICS
- Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)
- akta.pro secondary industry
- Teleradiology Platforms & Reading Workflow (HLACALAK)
Keywords
Where Nucleo is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Markets served
Nucleo business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations
Revenue model
- AI Diagnostics Platform: Automated cancer diagnostics solution for healthcare providers, likely delivered as a software-as-a-service platform integrated into clinical workflows.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Nucleo product offering
Product offeringCore offering
Nucleo offers an AI-powered software platform that automates analysis of CT scans for oncology care. The platform performs three core functions: (1) automatic detection and quantification of body composition (fat and muscle mass) for sarcopenia assessment, (2) precise and consistent measurement of tumor lesions, and (3) automated classification of target vs. non-target lesions according to RECIST criteria. It is sold as a recurring software platform to hospitals and oncology providers, with reported 95% agreement between its outputs and expert radiologists.
Product overview
Nucleo is a unified automated cancer diagnostics platform that analyzes CT scans for oncology care. The platform offers three integrated capabilities: (1) Body Composition and Sarcopenia Assessment for automatic detection and quantification of fat and muscle mass in CT scans; (2) Tumor Lesion Sizing for precise and consistent measurement of tumor lesions; and (3) Target vs. Non-Target Lesion Classification for automated classification of lesions according to RECIST criteria. The system operates faster than manual segmentation with 95% agreement between Nucleo and expert radiologists.
Differentiator
Problem solved
Functional benefit
Products and services
- Nucleo
Quantifiable outcome
- Faster than manual segmentation
- +1 more outcomes
Companies that use Nucleo
Customer profileNamed customers2 records
Segments1 record
Ideal customer profiles1 record
Nucleo technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature3 records
Nucleo partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- NVIDIAcoreNVIDIA is listed as an industry leader powering Nucleo's technology. NVIDIA provides GPU computing infrastructure and likely AI/ML tools that support the company's CT scan analysis platform.
- US HospitalscoreNucleo works with leading hospitals in the US, deploying its automated cancer diagnostics technology in clinical oncology workflows.
- International HospitalscoreNucleo partners with hospitals worldwide, extending its automated cancer diagnostics platform to international healthcare markets.
Scale indicators2 records
Recent moves5 records
Expansion highlights5 records
Nucleo competitors and assessment
Company assessmentDirect peers
- Annalise.ai: Annalise.ai provides comprehensive AI detection and quantification across CT and X-ray modalities, with oncology-relevant findings among its 130+ findings. Comparable in delivering CT AI analytics for hospital radiology and oncology workflows.
- Viz.ai: Viz.ai provides AI-powered imaging analytics (notably stroke and oncology) that integrate into hospital workflows to triage and coordinate care. Comparable to Nucleo in deploying AI imaging models to hospital radiology/oncology teams and using subscription enterprise sales.
- Aidoc: Aidoc is a leading AI radiology platform that analyzes CT and other imaging to flag acute findings (e.g., stroke, PE, oncology) for radiologists. Directly comparable to Nucleo in applying AI to CT scans for clinical oncology workflows and selling into hospital systems on a subscription basis.
- Paige.AI: Paige applies AI to pathology and oncology imaging for cancer detection and tumor characterization, with FDA-cleared products. Directly comparable to Nucleo in using AI for cancer diagnostics from medical images and targeting oncology clinical workflows in hospitals.
- Riverain Technologies (ClearRead): Riverain (ClearRead) offers AI tools that analyze chest CT and X-ray for nodule detection and improved reader efficiency, integrating into hospital PACS workflows. Comparable to Nucleo in applying AI to CT scans in oncology-relevant clinical workflows.
- Arterys: Arterys (now Tempus AI Radiology) provides a cloud-native AI imaging analytics platform with FDA-cleared oncology and cardiac imaging applications. Comparable in delivering automated quantitative analysis of CT/MR images to hospital radiology departments via SaaS.
- Perspectum: Perspectum develops AI-driven medical image quantification tools (e.g., body composition, organ fat/muscle) deployed in hospital and research settings. Comparable to Nucleo's body composition and quantitative oncology imaging analytics.
- Quibim: Quibim is a medical imaging AI company that extracts quantitative biomarkers (including body composition and tumor characterization) from CT and MRI for oncology and other specialties. Closely comparable to Nucleo's body composition, tumor sizing, and lesion classification use cases.
Broad incumbents
- RadNet (DeepHealth): RadNet operates one of the largest US imaging center networks and, through its DeepHealth subsidiary, develops AI tools for radiology including oncology. Comparable in deploying AI for CT scan analysis and oncology workflows, but as a large incumbent with diagnostic center operations.
- Tempus AI: Tempus is a broad AI-driven precision medicine company spanning oncology data, sequencing, and imaging analytics (including Arterys). Comparable in applying AI to oncology imaging and clinical decision support, though operating at much larger scale across multiple modalities.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key highlights6 records
Customer concentration
Nucleo social profiles
Digital presenceNucleo financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nucleo leadership team
Management profileNumber of profiles
Profiles3 records
Nucleo funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nucleo M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nucleo
What does Nucleo do?
Nucleo offers an AI-powered software platform that automates analysis of CT scans for oncology care. The platform performs three core functions: (1) automatic detection and quantification of body composition (fat and muscle mass) for sarcopenia assessment, (2) precise and consistent measurement of tumor lesions, and (3) automated classification of target vs. non-target lesions according to RECIST criteria. It is sold as a recurring software platform to hospitals and oncology providers, with reported 95% agreement between its outputs and expert radiologists.
Is Nucleo a public or private company?
Nucleo is a private company. It is classified as venture growth investor backed and is currently operating.
When was Nucleo founded?
Nucleo was founded in 2025. It employs 1 to 10 people.
Where is Nucleo based?
Nucleo is headquartered in San Francisco, United States, in the North America region.
How does Nucleo make money?
One revenue line is on record: AI Diagnostics Platform.
Who are Nucleo's main competitors?
Direct peers on record are Annalise.ai, Viz.ai, Aidoc, Paige.AI, Riverain Technologies (ClearRead), Arterys, Perspectum and Quibim. Broad incumbents are RadNet (DeepHealth) and Tempus AI.
Does Nucleo have an API?
No public API is recorded for Nucleo.
What industry is Nucleo in?
Nucleo's product category is AI Oncology Imaging Software. Its primary akta.pro industry code is HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage), with a secondary code of HLACALAK, Teleradiology Platforms & Reading Workflow. Its NAICS code is 621511 and its SIC code is 8071.